“Messenger RNA (mRNA) as a means for passive immunization has been extensively studied for years. Early studies since the 1990s showed that exogenous mRNA could direct protein expression in vivo, cementing mRNA as a promising drug platform technology , . Several studies later demonstrated the utility of mRNA in vaccine development and conferring protection against cancers  and infectious diseases , . Moreover, passive mRNA immunization also experiences fewer safety issues due to its non‐integrative and transient nature , the latter of which contributes to better and/or easier control of protein expression.
“The potential role of mRNA vaccination in the fight against SARS-CoV-2 is evidenced by ongoing COVID-19 Phase I vaccine trials conducted by several pharmaceutical companies, including Moderna Therapeutics’ mRNA-1273 vaccine , , which has yielding promising results. The feasibility of inhaled RNA for passive transfection has also been proven in a number of studies . On a mechanistic level, the inhaled RNA may lead to passive synthesis of non-infectious spike proteins using cell transfection machinery, hence leading to immunization of the individual.
“Though there are no conclusive or ongoing large scale clinical studies yet to prove the above hypothesis, we believe this proposal is worth exploring in our battle against COVID-19, given the significant number of already recovered individuals and the natural shedding of nonviable SARS-CoV-2 particles in the environment.”
I’m just going to go ahead and paste here from wiki about the ten year history of failure, failure, and nothing but failure from Moderna. It looks more like a money-laundering outfit than anything else. So ask yourself, how is it that after ten years of producing nothing, they were able to come up with a highly safe and highly effective Corona vaxx to enter into human trials just five WEEKS.
At the very end, you will read about the promise they made to Trump, and you will understand a great many things:
In 2010, ModeRNA Therapeutics was formed to commercialize the research of stem cell biologist Derrick Rossi. Rossi had developed a method of modifying mRNA by first transfecting it into human cells, then dedifferentiating it into bone marrow stem cells which could then be further differentiated into desired target cell types. Rossi approached fellow Harvard University faculty member Tim Springer, who solicited co-investment from Kenneth R. Chien, Bob Langer, and venture capital firm Flagship Ventures. Together they founded a company named from the combined terms “modified” and “RNA”.
In 2011, the CEO of Flagship Ventures (now Flagship Pioneering), Noubar Afeyan, brought in European pharma sales and operations executive Stéphane Bancel as CEO. Afeyan personally owned 19.5% of Moderna and was the largest single shareholder, while his fund, Flagship Pioneering, owned 18%.
In March 2013, Moderna and AstraZeneca signed a five-year exclusive option agreement to discover, develop, and commercialize mRNA for treatments in the therapeutic areas of cardiovascular, metabolic, and renal diseases, and selected targets for cancer. The agreement included a $240 million upfront payment to Moderna, a payment which was “one of the largest ever initial payments in a pharmaceutical industry licensing deal that does not involve a drug already being tested in clinical trials”, and an eight percent share in Moderna. As of May 2020, only one candidate has passed Phase I trials, a treatment for myocardial ischemia, labelled AZD8601.[a]
In 2013, Rossi, Chien and their team reported that they were able to improve heart function in mice and enhance their long-term survival with a “redirection of their [stem cell] differentiation toward cardiovascular cell types” in a significant step towards regenerative therapeutics for Moderna. In the same year and on the strength of the Nature Biotechnology paper, Moderna received from other investors $110 million.
In January 2014, Moderna and Alexion Pharmaceuticals entered a $125 million deal for orphan diseases in need of therapies. Alexion paid Moderna $100 million for ten product options to develop rare-disease treatments, including for Crigler-Najjar syndrome, using Moderna’s mRNA therapeutics platform. By 2016, Bancel told an audience of JPMorgan Chase investors that the work with Alexion would shortly enter human trials. However, by 2017, the program with Alexion had been scrapped as the animal trials showed that Moderna’s treatment would never be safe enough for humans.
In February 2016, a Nature editorial criticized Moderna for not publishing any peer-reviewed papers on its technology, unlike most other emerging and established biotech companies, and compared its approach to that of the controversially failed Theranos. In September 2018, Thrillist published an article titled, “Why This Secretive Tech Start-Up Could Be The Next Theranos”, criticizing its reputation for secrecy and the absence of scientific validation or independent peer-review of its research, though having the highest valuation of any U.S. private biotech company at more than $5 billion. A former Moderna scientist told Stat: “It’s a case of the emperor’s new clothes. They’re running an investment firm, and then hopefully it also develops a drug that’s successful.”
In 2018, the company rebranded as “Moderna Inc.” with the ticker symbol MRNA, and further increased its portfolio of vaccine development. In December 2018, Moderna became the largest biotech initial public offering in history, raising $621 million (27 million shares at $23 per share) on NASDAQ, and implying an overall valuation of $7.5 billion for the entire company. The year-end 2019 SEC filings showed that Moderna had accumulated losses of $1.5 billion since inception, with a loss of $514 million in 2019 alone, and had raised $3.2 billion in equity since 2010.
In March 2020, in a White House meeting between the Trump administration and pharmaceutical executives, Bancel told the president Moderna could have a COVID-19 vaccine ready in a few months. The next day, the FDA approved clinical trials for the Moderna vaccine candidate, with Moderna later receiving investment of $483 million from Operation Warp Speed. Moderna board member, Moncef Slaoui, was appointed head scientist for the Operation Warp Speed project.
This story has gone quite viral, and rightly so. Fifteen nuns having to abandon their monastery and load into vans to drive nonstop to Nebraska at the drop of a hat… Was it the new Ordinary? The archdiocese has denied any involvement. Which, if you think about it, a lack of involvement can be purposeful. Was it their confederation? Was there a visitation? Why were they at risk, having to fly to the protection of Bishop Conley? By the way, let’s give thanks that they are indeed safe and sound at Valparaiso in Nebraska.
But what will become of the Philly Carmel, and can anything be done about it?
Mother Pia, now alone in the monastery, is doing something about it. Today is the Feast of St. Joseph the Worker, and she is beginning a 30 day novena. Won’t you join me in joining her?
St. Joseph is the traditional patron of vocations for the Carmelites. There can’t be only one nun at a monastery – it’s canonically irregular. The minimum to be considered a stable community is three. If the Carmel is suppressed, the archdiocese can confiscate the property. In your charity, could you please send a short email or perhaps a quick phone call to Archbishop Perez and the Cardinal Prefect in Rome (see below).
Happy feast, and please pray.